Endomag receives FDA clearance for magnetic marker
Global healthcare company Endomag has announced it received 510(k) clearance from the FDA for its Magseed magnetic marker.
Magseed was developed to guide surgeons using the company’s Sentimag guidance system during a breast lumpectomy. According to Endomag, radiologists can place Magseed up to 30 days in advance of the actual surgical procedure.
“We are extremely pleased to receive this clearance and to have the opportunity to support U.S. clinicians and patients with our products,” Eric Mayes, PhD, Endomag CEO, said in a prepared statement. “In addition, we are excited to be launching our third product since we entered the European market in 2013. This clearance highlights our ability to deliver an exciting pipeline of innovative products to a global market.”
Endomag expects Magseed to be available this summer.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.